SYNTHESIS & EVAL OF 1,5,6 TRIAZACHRYSENE & 5,6,11 TRIAZACHRYSENE DERIVATIVES

合成

• 批准号: 7355172
• 负责人: EDMOND J LAVOIE
• 金额: $ 0.67万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2007-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7355172
• 关键词: SYNTHESIS; EVAL; TRIAZACHRYSENE; 11; DERIVATIVES

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our primary areas of research are drug discovery and development. Research currently includes the design and synthesis of novel topoisomerase I and II poisons as antineoplastic agents. Several potent topoisomerase poisons have been identified and studies are in progress to identify those with the greater potential to serve as clinical candidates. Research has also been undertaken on the synthesis of analogs of the cancer chemotherapeutic agent, hexamethylmelamine or Altretamine, as well as prodrugs of its suspect active metabolite. Mechanisms of carcinogenesis are being investigated by examining the potential role of metabolites of polycyclic aromatic compounds in cancer initiation and tumor growth.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。我们的主要研究领域是药物发现和开发。目前的研究包括新型拓扑异构酶I和II毒物作为抗肿瘤剂的设计和合成。已经确定了几种有效的拓扑异构酶毒药，并且正在进行研究以确定具有更大潜力的临床候选者的研究。还针对癌症化学治疗剂己酰胺或利列酰胺的类似物的合成以及其可疑活性代谢物的前药进行了研究。通过研究多环芳族化合物在癌症启动和肿瘤生长中的代谢物的潜在作用，正在研究致癌的机制。